Literature DB >> 10582700

Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.

R Chiari1, F Foury, E De Plaen, J F Baurain, J Thonnard, P G Coulie.   

Abstract

We have pursued our analysis of antigens recognized by autologous cytolytic T lymphocytes (CTLs) on the melanoma cells of patient LB33. This patient enjoys an unusually favorable evolution, which is associated with a strong and sustained antitumor CTL response. We reported previously the analysis of two melanoma cell lines, MEL.A and MEL.B, which were derived from metastases removed from the patient at 5 years' distance. Autologous CTL clones derived from blood lymphocytes recognized several antigens presented by different HLA class I molecules on MEL.A. The MEL.B cells resisted lysis by these CTLs because they have lost expression of most HLA molecules, suggesting that they were selected in vivo by the anti-MEL.A CTL response. One of the MEL.A antigens was shown to result from a point mutation in the tumor. Here we report the cloning of a gene that encodes two other MEL.A antigens. This new gene, MUM-2, is expressed ubiquitously. In the melanoma cells of patient LB33, it contains a point mutation that changes one amino acid in the translated protein. Two different antigenic peptides, one presented to CTL by HLA-B44 molecules and another by HLA-C6 molecules, overlap and contain the mutated residue. Gene MUM-2 is homologous to an essential yeast gene, bet5, that was recently shown to be implicated in the vesicular transport of proteins from the endoplasmic reticulum to the Golgi. In a mutant yeast with a disrupted bet5 gene, both the wild-type and the mutated MUM-2 genes could complement for bet5 function. These results indicate that the antigenic mutation does not destroy the function of the protein, a function that is conserved in eukaryotic cells. The identification of these antigens suggests that point mutations could be the major cause of the strong immunogenicity of MEL.A cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582700

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling.

Authors:  J M Angelastro; L Klimaschewski; S Tang; O V Vitolo; T A Weissman; L T Donlin; M L Shelanski; L A Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  Identification of HLA-Cw6.02 and HLA-Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries.

Authors:  Sara O Dionne; Douglas F Lake; William J Grimes; Margaret H Smith
Journal:  Immunogenetics       Date:  2004-08-12       Impact factor: 2.846

3.  Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.

Authors:  Tamara I Pestina; Phillip W Hargrove; Dennis Jay; John T Gray; Kelli M Boyd; Derek A Persons
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

Review 4.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 5.  Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.

Authors:  S D Martin; G Coukos; R A Holt; B H Nelson
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

6.  Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI).

Authors:  Manuela Hesse; Edith Willscher; Benjamin J Schmiedel; Stefan Posch; Ralph P Golbik; Martin S Staege
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

7.  Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient.

Authors:  Yoshinobu Ichiki; Takeshi Hanagiri; Mitsuhiro Takenoyama; Tetsuro Baba; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Masakazu Sugaya; Manabu Yasuda; Hidetaka Uramoro; Kosei Yasumoto
Journal:  Surg Today       Date:  2012-01-12       Impact factor: 2.549

Review 8.  Cancer immunotherapy targeting neoantigens.

Authors:  Yong-Chen Lu; Paul F Robbins
Journal:  Semin Immunol       Date:  2015-11-30       Impact factor: 11.130

9.  Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.

Authors:  Nisheeth Srivastava; Pramod K Srivastava
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

Review 10.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.